Sanofi targets eczema-treatment product Dupixent peak sales of over 13 billion euros
Paris: French healthcare group Sanofi, which lagged rivals in the race for COVID-19 vaccines, raised on Tuesday its peak sales target for eczema-treatment product Dupixent to more than 13 billion euros ($14.3 billion).
"This new ambition does not include potential for additional sales ambition upgrade from chronic obstructive pulmonary disease (COPD), with pivotal readouts anticipated in 2023," Sanofi said in a statement.
This month, analysts at investment bank JP Morgan had said they expected Sanofi to raise its peak sales guidance for Dupixent to about $15 billion.
Read also: Sanofi joins hands with Prellis Biologics
Sanofi is working with British partner GlaxoSmithKline to develop a COVID-19 vaccine.
Sanofi also announced on Tuesday a partnership with U.S company IGM Biosciences in the field of treatments for oncology, immunology and inflammation.
Read also: Sanofi gets Japenese nod for Xenpozyme to treat acid sphingomyelinase deficiency
